Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Sotrovimab  COVID-19 treatment studies for Sotrovimab  C19 studies: Sotrovimab  Sotrovimab   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 sotrovimab studies
Outcomes in sotrovimab studies. Efficacy is variant dependent. In Vitro studies suggest lower efficacy for omicron. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 46% 2 1,417 Improvement, Studies, Patients Relative Risk Mortality 46% 2 1,417 Ventilation 89% 1 1,057 ICU admission 95% 1 1,057 RCTs 46% 2 1,417 RCT mortality 46% 2 1,417 Early 89% 1 1,057 Late -2% 1 360 Sotrovimab for COVID-19 c19sv.com Jan 21, 2022 Favors sotrovimab Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 89% 0.11 [0.01-2.06] death 0/528 4/529 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Early treatment 89% 0.11 [0.01-2.06] 0/528 4/529 89% improvement Self (DB RCT) -2% 1.02 [0.48-2.17] death 14/182 13/178 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.96 Late treatment -2% 1.02 [0.48-2.17] 14/182 13/178 -2% improvement All studies 46% 0.54 [0.08-3.85] 14/710 17/707 46% improvement 2 sotrovimab COVID-19 studies c19sv.com Jan 21, 2022 Tau​2 = 1.28, I​2 = 52.0%, p = 0.55 Effect extraction pre-specified Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 89% 0.11 [0.01-2.06] 0/528 4/529 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Early treatment 89% 0.11 [0.01-2.06] 0/528 4/529 89% improvement Self (DB RCT) -2% 1.02 [0.48-2.17] 14/182 13/178 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.96 Late treatment -2% 1.02 [0.48-2.17] 14/182 13/178 -2% improvement All studies 46% 0.54 [0.08-3.85] 14/710 17/707 46% improvement 2 sotrovimab COVID-19 mortality results c19sv.com Jan 21, 2022 Tau​2 = 1.28, I​2 = 52.0%, p = 0.55 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 89% 0.11 [0.01-2.06] 0/528 4/529 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Early treatment 89% 0.11 [0.01-2.06] 0/528 4/529 89% improvement All studies 89% 0.11 [0.01-2.06] 0/528 4/529 89% improvement 1 sotrovimab COVID-19 mechanical ventilation result c19sv.com Jan 21, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 95% 0.05 [0.00-0.90] 0/528 9/529 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.042 Early treatment 95% 0.05 [0.00-0.90] 0/528 9/529 95% improvement All studies 95% 0.05 [0.00-0.90] 0/528 9/529 95% improvement 1 sotrovimab COVID-19 ICU result c19sv.com Jan 21, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.042 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 81% 0.19 [0.07-0.55] hosp. 4/291 21/292 Improvement, RR [CI] Treatment Control Tau​2 = 0.00; I​2 = 0.0% Early treatment 81% 0.19 [0.07-0.55] 4/291 21/292 81% improvement All studies 81% 0.19 [0.07-0.55] 4/291 21/292 81% improvement 1 sotrovimab COVID-19 hospitalization result c19sv.com Dec 6, 2021 Tau​2 = 0.00; I​2 = 0.0%; Z = 3.07 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 89% 0.11 [0.01-2.06] death 0/528 4/529 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Early treatment 89% 0.11 [0.01-2.06] 0/528 4/529 89% improvement Self (DB RCT) -2% 1.02 [0.48-2.17] death 14/182 13/178 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.96 Late treatment -2% 1.02 [0.48-2.17] 14/182 13/178 -2% improvement All studies 46% 0.54 [0.08-3.85] 14/710 17/707 46% improvement 2 sotrovimab COVID-19 serious outcomes c19sv.com Jan 21, 2022 Tau​2 = 1.28, I​2 = 52.0%, p = 0.55 Effect extraction pre-specified Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Self (DB RCT) 11% 0.89 [0.73-1.10] no recov. 22/160 27/178 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Late treatment 11% 0.89 [0.73-1.10] 22/160 27/178 11% improvement All studies 11% 0.89 [0.53-1.50] 22/160 27/178 11% improvement 1 sotrovimab COVID-19 recovery result c19sv.com Jan 21, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.68 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 89% 0.11 [0.01-2.06] death 0/528 4/529 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Early treatment 89% 0.11 [0.01-2.06] 0/528 4/529 89% improvement Self (DB RCT) -2% 1.02 [0.48-2.17] death 14/182 13/178 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.96 Late treatment -2% 1.02 [0.48-2.17] 14/182 13/178 -2% improvement All studies 46% 0.54 [0.08-3.85] 14/710 17/707 46% improvement 2 sotrovimab COVID-19 Randomized Controlled Trials c19sv.com Jan 21, 2022 Tau​2 = 1.28, I​2 = 52.0%, p = 0.55 Effect extraction pre-specified Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 89% 0.11 [0.01-2.06] 0/528 4/529 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Early treatment 89% 0.11 [0.01-2.06] 0/528 4/529 89% improvement Self (DB RCT) -2% 1.02 [0.48-2.17] 14/182 13/178 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.96 Late treatment -2% 1.02 [0.48-2.17] 14/182 13/178 -2% improvement All studies 46% 0.54 [0.08-3.85] 14/710 17/707 46% improvement 2 sotrovimab COVID-19 RCT mortality results c19sv.com Jan 21, 2022 Tau​2 = 1.28, I​2 = 52.0%, p = 0.55 Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 89% 0.11 [0.01-2.06] death 0/528 4/529 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.14 Early treatment 89% 0.11 [0.01-2.06] 0/528 4/529 89% improvement Self (DB RCT) -2% 1.02 [0.48-2.17] death 14/182 13/178 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.96 Late treatment -2% 1.02 [0.48-2.17] 14/182 13/178 -2% improvement All studies 46% 0.54 [0.08-3.85] 14/710 17/707 46% improvement 2 sotrovimab COVID-19 peer reviewed trials c19sv.com Jan 21, 2022 Tau​2 = 1.28, I​2 = 52.0%, p = 0.55 Effect extraction pre-specified Favors sotrovimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gupta (DB RCT) 89% 0.11 [0.01-2.06] death 0/528 4/529 Improvement, RR [CI] Treatment Control Gupta (DB RCT) 89% 0.11 [0.01-2.06] ventilation 0/528 4/529 Gupta (DB RCT) 95% 0.05 [0.00-0.90] ICU 0/528 9/529 Gupta (DB RCT) 79% 0.21 [0.09-0.50] hosp./death 6/528 30/529 Self (DB RCT) -2% 1.02 [0.48-2.17] death 14/182 13/178 Self (DB RCT) 11% 0.89 [0.73-1.10] no recov. 22/160 27/178 Self (DB RCT) 7% 0.93 [0.63-1.35] no recov. 160 (n) 178 (n) sotrovimab COVID-19 outcomes c19sv.com Jan 21, 2022 Favors sotrovimab Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit